 |
Cadence Pharmaceuticals' CEO Ted Schroeder To Present At The JMP Securities 11th Annual Research Conference In San Francisco On May 15, 2012
May 11, 2012
|
9.9 KB |
|
| |
SAN DIEGO, May 11, 2012 /PRNewswire/ -- Cadence Pharmaceuticals, Inc. (NASDAQ: CADX), a biopharmaceutical company focused on acquiring, in-licensing, developing and commercializing proprietary product candidates principally for use in the hospital setting, announced today that the company's President and CEO Ted Schroeder will present the company's...
|
|
Cadence Pharmaceuticals Reports First Quarter 2012 Financial Results
May 3, 2012
|
22.2 KB |
|
| |
SAN DIEGO, May 3, 2012 /PRNewswire/ -- Cadence Pharmaceuticals, Inc. (NASDAQ: CADX), a biopharmaceutical company focused on acquiring, in-licensing, developing and commercializing proprietary products principally for use in the hospital setting, today reported financial results for the first quarter ended March 31, 2012.
During the first q...
|
|
Cadence Pharmaceuticals To Present At The Deutsche Bank Securities, Inc. 37th Annual Health Care Conference In Boston On May 8, 2012
May 2, 2012
|
9.9 KB |
|
| |
SAN DIEGO, May 2, 2012 /PRNewswire/ -- Cadence Pharmaceuticals, Inc. (NASDAQ: CADX), a biopharmaceutical company focused on in-licensing, developing and commercializing proprietary product candidates principally for use in the hospital setting, announced today that the company's Chief Commercial Officer Scott Byrd will present the company's corpora...
|
|
Cadence Pharmaceuticals to Host Conference Call and Webcast to Discuss First Quarter 2012 Financial Results on May 3, 2012
Apr 24, 2012
|
9.9 KB |
|
| |
SAN DIEGO, April 24, 2012 /PRNewswire/ -- Cadence Pharmaceuticals, Inc. (NASDAQ: CADX), a biopharmaceutical company focused on acquiring, in-licensing, developing and commercializing proprietary product candidates principally for use in the hospital setting, today announced that it will release its first quarter ended March 31, 2012 financial resul...
|
|
Cadence Pharmaceuticals Reports Fourth Quarter and Full Year 2011 Financial Results
Mar 12, 2012
|
28.7 KB |
|
| |
SAN DIEGO, March 12, 2012 /PRNewswire/ -- Cadence Pharmaceuticals, Inc. (NASDAQ: CADX), a biopharmaceutical company focused on acquiring, in-licensing, developing and commercializing proprietary products principally for use in the hospital setting, today reported financial results for the fourth quarter and year ended December 31, 2011.
Highlig...
|
|
Cadence Pharmaceuticals to Host Conference Call and Webcast to Discuss Fourth Quarter and Full Year 2011 Financial Results on March 12, 2012
Mar 5, 2012
|
9.9 KB |
|
| |
SAN DIEGO, March 5, 2012 /PRNewswire/ -- Cadence Pharmaceuticals, Inc. (NASDAQ: CADX), a biopharmaceutical company focused on in-licensing, developing and commercializing proprietary product candidates principally for use in the hospital setting, today announced that it will release its fourth quarter and full year ended December 31, 2011 financial...
|
|
Cadence Pharmaceuticals' CEO Ted Schroeder to Present at the Cowen and Company 32nd Annual Health Care Conference in Boston on March 7, 2012
Feb 29, 2012
|
10.0 KB |
|
| |
SAN DIEGO, Feb. 29, 2012 /PRNewswire/ -- Cadence Pharmaceuticals, Inc. (NASDAQ: CADX), a biopharmaceutical company focused on in-licensing, developing and commercializing proprietary product candidates principally for use in the hospital setting, announced today that the company's President and CEO Ted Schroeder will present the company's corporate...
|
|
Cadence Pharmaceuticals CEO Ted Schroeder to Present at the Leerink Swann 2012 Global Healthcare Conference on February 15, 2012
Feb 9, 2012
|
9.9 KB |
|
| |
SAN DIEGO, Feb. 9, 2012 /PRNewswire/ -- Cadence Pharmaceuticals, Inc. (NASDAQ: CADX), a biopharmaceutical company focused on in-licensing, developing and commercializing proprietary products principally for use in the hospital setting, announced today that the company's President and CEO Ted Schroeder will present the company's corporate overview o...
|
|
Cadence Pharmaceuticals Announces Voluntary Recall of One Lot of OFIRMEV® (Acetaminophen) Injection
Feb 6, 2012
|
14.0 KB |
|
| |
SAN DIEGO, Feb. 6, 2012 /PRNewswire/ -- Cadence Pharmaceuticals, Inc. (NASDAQ: CADX), a biopharmaceutical company focused on in-licensing, developing and commercializing proprietary products principally for use in the hospital setting, announced today the voluntary recall of a single lot of OFIRMEV® (acetaminophen) injection. Cadence has notif...
|
|
Cadence Pharmaceuticals Announces Completion of Public Offering of Common Stock, Including Full Exercise of Over-Allotment Option by Underwriters
Nov 22, 2011
|
11.6 KB |
|
| |
SAN DIEGO, Nov. 22, 2011 /PRNewswire/ -- Cadence Pharmaceuticals, Inc. (Nasdaq: CADX) today announced the closing of its previously announced public offering of 21,800,000 shares of its common stock, including 2,800,000 shares sold pursuant to the full exercise of an over-allotment option previously granted to the underwriters, at a public offering...
|
|
Cadence Pharmaceuticals Announces Pricing of Public Offering of Common Stock
Nov 15, 2011
|
11.7 KB |
|
| |
SAN DIEGO, Nov. 15, 2011 /PRNewswire/ -- Cadence Pharmaceuticals, Inc. (Nasdaq: CADX) today announced that it has priced an underwritten public offering of 19,000,000 shares of its common stock at a price to the public of $3.75 per share. The net proceeds from the sale of the shares, after deducting the underwriting discounts and commissions and e...
|
|
Cadence Pharmaceuticals Announces Proposed Public Offering of Common Stock
Nov 14, 2011
|
11.5 KB |
|
| |
SAN DIEGO, Nov. 14, 2011 /PRNewswire/ -- Cadence Pharmaceuticals, Inc. (Nasdaq: CADX) today announced its intention to offer and sell $75 million worth of shares of its common stock in an underwritten public offering. Cadence also expects to grant to the underwriters for the offering a 30-day option to purchase additional shares of common stock to...
|
|
Cadence Pharmaceuticals Reports Third Quarter 2011 Financial Results
Nov 3, 2011
|
23.1 KB |
|
| |
SAN DIEGO, Nov. 3, 2011 /PRNewswire/ -- Cadence Pharmaceuticals, Inc. (NASDAQ: CADX), a biopharmaceutical company focused on in-licensing, developing and commercializing proprietary products principally for use in the hospital setting, today reported financial results for the three and nine months ended September 30, 2011.
For the third quarter...
|
|
Cadence Pharmaceuticals' CEO Ted Schroeder to Present at the Credit Suisse Healthcare Conference on November 9, 2011
Nov 2, 2011
|
9.7 KB |
|
| |
SAN DIEGO, Nov. 2, 2011 /PRNewswire/ -- Cadence Pharmaceuticals, Inc. (NASDAQ: CADX), a biopharmaceutical company focused on in-licensing, developing and commercializing proprietary products principally for use in the hospital setting, today announced that the company's President and CEO Ted Schroeder will present the company's corporate overview o...
|
|
Cadence Pharmaceuticals to Host Conference Call and Webcast to Discuss Third Quarter 2011 Financial Results on November 3, 2011
Oct 27, 2011
|
9.9 KB |
|
| |
SAN DIEGO, Oct. 27, 2011 /PRNewswire/ -- Cadence Pharmaceuticals, Inc. (NASDAQ: CADX), a biopharmaceutical company focused on in-licensing, developing and commercializing proprietary products principally for use in the hospital setting, today announced that it will release its third quarter ended September 30, 2011 financial results on Thursday, No...
|
|
Cadence Pharmaceuticals to Present at Three Investment Conferences During the Month of September 2011
Aug 31, 2011
|
10.3 KB |
|
| |
SAN DIEGO, Aug. 31, 2011 /PRNewswire/ -- Cadence Pharmaceuticals, Inc. (NASDAQ: CADX), a biopharmaceutical company focused on in-licensing, developing and commercializing proprietary product candidates principally for use in the hospital setting, announced today that the company will present a corporate overview at the following investment conferen...
|
|
Cadence Pharmaceuticals Reports Second Quarter 2011 Financial Results
Aug 3, 2011
|
23.8 KB |
|
| |
SAN DIEGO, Aug. 3, 2011 /PRNewswire/ -- Cadence Pharmaceuticals, Inc. (NASDAQ: CADX), a biopharmaceutical company focused on in-licensing, developing and commercializing proprietary products principally for use in the hospital setting, today reported financial results for the three and six months ended June 30, 2011.
Cadence commercially launch...
|
|
Cadence Pharmaceuticals to Present at Two Investment Conferences During the Month of August 2011
Aug 2, 2011
|
10.2 KB |
|
| |
SAN DIEGO, Aug. 2, 2011 /PRNewswire/ -- Cadence Pharmaceuticals, Inc. (NASDAQ: CADX), a biopharmaceutical company focused on in-licensing, developing and commercializing proprietary products principally for use in the hospital setting, announced today that the company will present a corporate overview at the following investment conferences during ...
|
|
Cadence Pharmaceuticals Reaffirms FDA-Approved Dosing Recommendations for OFIRMEV® (acetaminophen) Injection
Jul 28, 2011
|
13.3 KB |
|
| |
SAN DIEGO, July 28, 2011 /PRNewswire/ -- Cadence Pharmaceuticals, Inc. (NASDAQ: CADX) today confirmed that the U.S. Food and Drug Administration (FDA) approved dosing recommendations for OFIRMEV® (acetaminophen) injection remains 4,000 mg per day for adults and adolescents weighing at least 50 kg.
Cadence's announcement follows the issuance...
|
|
Cadence Pharmaceuticals to Host Conference Call and Webcast to Discuss Second Quarter 2011 Financial Results on August 3, 2011
Jul 27, 2011
|
9.9 KB |
|
| |
SAN DIEGO, July 27, 2011 /PRNewswire/ -- Cadence Pharmaceuticals, Inc. (NASDAQ: CADX), a biopharmaceutical company focused on in-licensing, developing and commercializing proprietary products principally for use in the hospital setting, today announced that it will release its second quarter ended June 30, 2011 financial results on Wednesday, Augus...
|
|
|
